Tag: FDA

63 posts found

Medmonitor

FDA Approves Kloxxado for Opioid Overdose

A new 8 mg naloxone nasal spray will soon be available, which is the largest naloxone dose approved by the FDA to date.

Medmonitor

FDA and CDC Recommend Resuming Use of Johnson & Johnson COVID-19 Vaccine

After reviewing six rare cases of blood clots after 7 million doses, current data indicates the vaccine is safe.

Medmonitor

FDA Approves New Acetaminophen Injection Dose

A new 500mg injection will soon be available.

Medmonitor

FDA Approves Posimir for Post-Surgical Pain Relief

A novel bupivacaine formulation works as a 72-hour local anesthetic following shoulder surgery.

Clinical Insights

Xeljanz Could Increase the Risk of Heart Problems and Cancer

New data from a safety trial creates concern surrounding the rheumatoid arthritis drug.

Medmonitor

COVID-19 Mutations Impact Testing

False negatives may be reported due to genetic variations of the virus.

Medmonitor

FDA Authorizes Two COVID-19 Vaccines, At-Home Test, More Treatments

Vaccine candidates from Pfizer-BioNTech and Moderna received EUAs, as did the first at-home test that delivers results in 30 minutes, and two treatments for the virus.

Medmonitor

FDA Approves Veklury for COVID-19, Issues EUA for Bamlanivimab

Veklury is approved for hospitalized patients, while bamlanivimab is being investigated in mild-to-moderate cases of COVID-19.

Medmonitor

FDA Requires Boxed Warning Update for Benzodiazepines

Even at recommended doses, benzodiazepine use can lead to misuse, abuse, and addiction.

Medmonitor

FDA Approves Two New Opioids

Olinvyk injections and Qdolo oral solution are approved for the management of acute pain.

Medmonitor

FDA Issues Naloxone Recommendations for Opioids and OUD Drugs

The FDA recommends healthcare professionals co-prescribe the opioid overdose reversal drug with all opioid prescriptions.

Medmonitor

FDA Approves Hulio for Rheumatoid Arthritis and More

Subcutaneous injections of the new biologic, adalimumab-fkjp, were approved for seven indications.

COVID-19: Hydroxychloroquine and Remdesivir Updates

The malaria drug loses an EUA for COVID-19, while the FDA warns of drug interactions that can reduce antiviral effectiveness.

Medmonitor

FDA Approves Elyxyb Oral Solution for Migraines

Elyxyb (celecoxib) is an NSAID for the acute treatment of migraine with or without aura.

Clinical Insights

Remdesivir a Potential Treatment for COVID-19?

The FDA allows emergency use in response to positive trials, but more research is needed.

Prev 1 2 3 4 5 Next